Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
13.12
+0.73 (5.89%)
At close: May 12, 2025, 4:00 PM
13.06
-0.06 (-0.46%)
After-hours: May 12, 2025, 5:14 PM EDT
Viridian Therapeutics Revenue
Viridian Therapeutics had revenue of $72.00K in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to $302.00K, up 4.86% year-over-year. In the year 2024, Viridian Therapeutics had annual revenue of $302.00K, down -3.82%.
Revenue (ttm)
$302.00K
Revenue Growth
+4.86%
P/S Ratio
3,544.66
Revenue / Employee
$2,112
Employees
143
Market Cap
1.07B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 302.00K | -12.00K | -3.82% |
Dec 31, 2023 | 314.00K | -1.46M | -82.28% |
Dec 31, 2022 | 1.77M | -1.19M | -40.20% |
Dec 31, 2021 | 2.96M | 1.91M | 182.19% |
Dec 31, 2020 | 1.05M | -3.41M | -76.46% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
VRDN News
- 5 days ago - Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED) - Business Wire
- 6 days ago - Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results - Business Wire
- 10 days ago - Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors - Business Wire
- 2 months ago - Viridian Therapeutics: Positive Data In TED, Strong Cash Position, 1.5-Year Window - Seeking Alpha
- 2 months ago - Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results - Business Wire
- 4 months ago - Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease - Business Wire
- 5 months ago - Viridian: Positive Chronic TED Data Likely To Lead To BLA Filing In Second Half Of 2025 (Rating Upgrade) - Seeking Alpha